Abstract
Introduction
This prospective, single-arm, crossover pharmacodynamic study assessed the effect of Bayer® low-dose enteric-coated aspirin 81 mg tablets (LD EC-ASA) (Bayer AG, Leverkusen, North Rhine-Westphalia, Germany) compared to Vazalore® low-dose phospholipid-aspirin liquid-filled 81 mg capsules (LD PL-ASA) (PLx Pharma Inc., Sparta, NJ, USA) on platelet reactivity with respect to aspirin reaction units (ARU).
Methods
Forty-seven healthy volunteers were recruited. Platelet function was evaluated with the VerifyNow™ ARU assay (Werfen, Bedford, MA, USA) and assessed post-initiation of Bayer® LD EC-ASA daily for 14 days, with a washout period of 28 days, followed by Vazalore® LD PL-ASA daily for 14 days, again followed by ARU testing.
Results
Participants on LD EC-ASA had a mean ARU score of 426, with 19.1% of participants having an ARU > 550; patients on LD PL-ASA derived a mean ARU score of 435, with 14.9% achieving an ARU > 550. There were no significant differences in aspirin resistance (ARU > 550) according to the formulation (Bayer® LD EC-ASA vs. Vazalore® LD PL-ASA) used. Aspirin resistance was independent of ethnicity regardless of the formulation used. In addition, there were no significant associations between body surface area (BSA) and Bayer® LD EC-ASA ARU value (p value 0.788) or Vazalore® LD PL-ASA ARU value (p value 0.477). No patients experienced any serious adverse events or treatment-emergent adverse events.
Conclusions
There were no significant differences in aspirin resistance between Bayer® LD EC-ASA and Vazalore® LD PL-ASA. This dedicated pharmacodynamic study could potentially be informative and applicable for Trinidadian patients on dual antiplatelet therapy (DAPT). Further studies are required to confirm these exploratory findings.
Trial Registration
ClinicalTrials.gov identifier, NCT06228820, prospectively registered 1/18/2024.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and aspirin is recommended in patients with coronary artery disease to reduce the risk of major adverse cardiovascular events (MACE). |
Aspirin resistance (AR) describes a phenomenon whereby patients receiving aspirin therapy respond in a suboptimal manner, evidenced by continued MACE and/or the lack of attenuated platelet reactivity. Studies demonstrate that approximately 25% of patients with vascular disease are resistant to aspirin therapy, conferring an almost fourfold increased risk of MACE. |
What was learned from the study? |
Participants on Bayer® low-dose enteric-coated aspirin 81 mg tablets (LD EC-ASA) (Bayer AG, Leverkusen, North Rhine-Westphalia, Germany) had a mean aspirin reaction unit (ARU) score of 426, with 19.1% having an ARU > 550; patients on Vazalore® low-dose phospholipid-aspirin liquid-filled 81 mg capsules (LD PL-ASA) (PLx Pharma Inc., Sparta, NJ, USA) derived a mean ARU score of 435, with 14.9% achieving an ARU > 550. There were no significant differences in AR (ARU > 550) according to the formulation (Bayer® LD EC-ASA vs. Vazalore® LD PL-ASA) used. |
This dedicated pharmacodynamic study could potentially be informative and applicable for Trinidadian patients on dual antiplatelet therapy. |
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide, and aspirin is recommended in patients with coronary artery disease (CAD) to attenuate major adverse cardiovascular events (MACE) [1,2,3]. Several studies reveal discordant findings regarding the preferred dosage and formulation of aspirin in patients with CAD with varying risk–benefit profiles [4,5,6,7]. Absorption of enteric-coated aspirin (EC-ASA) tablets is suboptimal, which can result in decreased clinical effectiveness. Phospholipid-aspirin liquid-filled capsules (PL-ASA) are a novel immediate-release formulation, approved by the Federal Drug Administration (FDA) in 2022, that can mitigate adverse gastrointestinal effects [8].
High on-treatment platelet reactivity (HPR) to clopidogrel is significantly higher in South Asians (> 60% of patients), which has severe clinical repercussions considering the cardiovascular disease pandemic [9, 10]. South Asians are four times as likely to carry the CYP2C19*2 allele than Caribbean Black patients [9, 11]. The combination of aspirin resistance (AR) with HPR may be potentially catastrophic in these patients with CVD, alluding to a “double-hit” phenomenon.
We conducted this exploratory pilot study to assess the antiplatelet pharmacodynamic effect of Bayer® low-dose enteric-coated aspirin 81 mg tablets (LD EC-ASA) (Bayer AG, Leverkusen, North Rhine-Westphalia, Germany) compared to Vazalore® low-dose phospholipid-aspirin liquid-filled 81 mg capsules (LD PL-ASA) (PLx Pharma Inc., Sparta, NJ, USA) on platelet reactivity with respect to aspirin reaction units (ARU) and in a Trinidadian subpopulation comprising healthy participants.
Methods
Study Design and Patient Population
The study complied with the tenets of Declaration of Helsinki, International Conference on Harmonization, Good Clinical Practice (ICH-GCP), and was authorized by the Campus Research Ethics Committee (CREC) of the University of the West Indies, St. Augustine (UWI STA), Trinidad (CEC1153/06/19) [12, 13]. All healthy volunteers consented to participate in a prospective, open-label, single-arm crossover study that evaluated the effect of Bayer® LD EC-ASA (Bayer AG, Leverkusen, North Rhine-Westphalia, Germany) daily for 14 days, with a washout period of 28 days, followed by Vazalore® LD PL-ASA (PLx Pharma Inc., Sparta, NJ, USA) daily for 14 days, again followed by aspirin reaction unit (ARU) testing. Healthy volunteers were screened and recruited between January 2024 and March 2024 at the ambulatory outpatient center at our institution, Trinidad Institute of Medical Technology (TIMT), Trinidad and Tobago). They met selection criteria if they were above 18 years of age and healthy, with no pre-existing medical condition. Pre-specified exclusion included any aspirin reaction, allergy or hypersensitivity, declining participation, and any prior medical condition. Patients were instructed to self-administer aspirin during or shortly after meal ingestion. The patients were monitored for 28 days post-completion to evaluate for any serious adverse events.
VerifyNow™ Aspirin Reaction Unit (ARU) Testing
Aspirin was withheld on the day of testing, almost 18 h before baseline blood sampling, which ensured the determination of trough levels. Whole blood samples were acquired by antecubital puncture utilizing a 21-gauge needle (Greiner Bio-One North America, Monroe, NC, USA, #450097). They were placed into Vacuette (Greiner Bio-One North America, Monroe, NC, USA) citrated blood collecting vials (containing 3.8% trisodium citrate) (#454322) after discarding the first 5 ml of waste. Blinded clinical research associates processed samples. VerifyNow™ ARU assays (Werfen, Bedford, MA, USA) were utilized in accordance with standardized protocols [14, 15]. The assay reports the results as aspirin reaction units (ARU). The pre-specified level of aspirin resistance was ≥ 550 ARU. The enrolled patients were then treated with Bayer® aspirin 81 mg once daily for 14 days, with a 28-day washout period, followed by Vazalore® aspirin 81 mg once daily for 14 days, with pill accountability verified by the clinical research associate (Fig. 1).
Patient Interview and Case Report Form
The patients’ demographic data were transcribed on a case report form (CRF). They included the patient’s age, gender, ethnicity, anthropometric data, respective ARUs on Bayer® LD EC-ASA and Vazalore® LD PL-ASA, and adverse drug reactions such as gastrointestinal upset or severe bleeding.
Statistical Analysis
The calculated sample size was 47 patients based on a paired proportion sample, an alpha (α) value of 0.05, power of 80%, estimated baseline prevalence of 45% of ARU > 550, and an absolute delta of 22.5% (expected prevalence of 22.5% of ARU > 550) [16]. The accrued data were assessed using descriptive statistics as well as SPSS version 28.0 software. The descriptive data were presented using frequencies with percentages for categorical variables, means for continuous data, and medians for ordinal data. Independent comparisons were performed using Fisher’s exact test for categorical variables. Pairwise comparisons were made using McNemar’s test for paired proportions, and Wilcoxon signed-rank test for ordinal data. The Kruskal–Wallis test was used to compare medians across three categories. Spearman’s correlation was used to evaluate associations between non-normal continuous variables. A p value of < 0.05 was used to indicate statistical significance. All participants were 100% compliant with administration of both study drugs, verified with pill accountability, and completed this study without any protocol deviations.
Results
Of a total of 47 healthy participants, the average age was 34 (standard deviation (SD) ± 10.9) years, with 55% representative of the male gender. Caribbean South Asians comprised 68%, Caribbean Blacks 17%, and mixed and/or interracial 15% of the study population. The mean body mass index (BMI) was 25.9 (SD ± 6.11) kg/m2, and the mean body surface area (BSA) was 1.84 (SD ± 0.23) m2 (Table 1). There were no statistically significant differences in aspirin resistance (ARU > 550) according to the brand (Bayer® vs. Vazalore®) used (Fig. 2, Table 2). Aspirin resistance was independent of ethnicity regardless of the brand used (Table 3). In addition, there were no significant associations between body surface area (BSA) and Bayer® ARU value (p value 0.788) or Vazalore® ARU value (p value 0.477) (Table 3). No patients experienced any serious adverse events nor treatment-emergent adverse events during their active participation and follow-up period of 28 days.
Discussion
Acetylsalicylic acid irreversibly inhibits the activity of platelet cyclooxygenase-1 (COX-1), thereby inhibiting the platelet production of thromboxane A2 (TXA2) [17, 18]. By preventing the formation of TXA2, ASA reduces platelet activation and aggregation promoted by TXA2 [19, 20].
ASA is frequently prescribed with meals to alleviate dyspeptic symptoms. EC-ASA is erratically absorbed, and the bioavailability decreases with the ingestion of food. The novel lipid-aspirin complex (PL-ASA) liquid capsule formulation is an immediate-release aspirin with consistent bioavailability that has been specifically designed to attenuate gastrointestinal (GI) effects [6, 21]. There has been a recent paradigm shift in the pharmaceutical development and commercialization of phosphatidylcholine–nonsteroidal anti-inflammatory drugs (PC-NSAIDs), namely Vazalore®, that reduce GI injury, such as ulcers, without compromising therapeutic activity [22, 23]. The PC-NSAID complex (PLxGuard™ delivery platform, PLx Pharma Inc., Sparta, NJ, USA) remains intact in low pH environments, such as the stomach, limiting free aspirin contact with the gastric mucosa [24]. A recent prospective, randomized crossover study demonstrated that LD PL-ASA resulted in faster platelet inhibition compared with EC-ASA, which could not be attributed to ASA formulation [25]. Lipid excipients used in LP-ASA did not impair the pharmacodynamic effects or alter platelet function [26].
Aspirin resistance (AR) describes a phenomenon where patients receiving aspirin therapy respond in a suboptimal manner, evidenced by continued MACE and/or the lack of attenuated platelet reactivity. Studies demonstrate that approximately 25% of patients with vascular disease are resistant to aspirin therapy, conferring an almost fourfold increased risk of MACE [27]. Novel antithrombotic strategies incorporating clopidogrel, ticagrelor, and direct oral anticoagulants such as rivaroxaban improve outcomes in patients with vascular disease [27]. Many investigators postulate that AR is implicated in major adverse cardiovascular and cerebrovascular events (MACCE) [28,29,30,31]. AR is a heterogeneous entity and remains challenging to define clinically or biochemically [32]. Fundamentally, it is the inability of aspirin to attenuate TXA2 production with effects on platelet activation and aggregation. Contributory factors include inappropriate dosage dose, drug–drug interactions, polymorphisms of COX-1 genes regulating thromboxane biosynthesis, upregulation of other sources of thromboxane production, and accentuated platelet turnover [33, 34]. Conditions that influence AR include age, gender, acute coronary syndromes, heart failure, chronic kidney disease, anemia, diabetes mellitus, tobacco use, concomitant NSAID use, malabsorption, and genetic factors [35, 36]. Compliance is also a key factor in the suboptimal response to ASA [28]. Medication compliance is a critical aspect of this phenomenon and potentially contributes to its overreporting. Thus, counseling patients with respect to the benefits of antiplatelet therapy may enhance compliance [37]. Our study did not show any statistically significant association with gender, ethnicity, body mass index, or body surface area. Our participants’ compliance was verified by pill accountability by the consultant cardiologists.
The VerifyNow™ (VN) (Werfen, Bedford, MA, USA) is a bedside, point-of-care platelet function analyzer in which a blood sample is exposed to fibrinogen-coated beads and platelet agonists. Light transmission is accentuated with platelet aggregation, signifying the absence of an antiplatelet effect and suggesting aspirin resistance [33]. VerifyNow™ test results are expressed in aspirin reaction units (ARU), and the cutoff for determination of aspirin resistance was ≥ 550 ARU [14]. The prevalence of aspirin resistance is estimated to be between 5.5 and 60% in patients, contingent on the definition, assessment, and parameters utilized [16]. When the VN-ARU test is used, the prevalence ranges from 7 to 27% [38, 39]. However, using the “gold standard” methodology, optical aggregometry, the prevalence is about 0.4–9%. Our study displayed similar results, with a mean ARU score of 426 and 19.1% of participants having an ARU > 550 on LD EC-ASA. LD PL-ASA derived a mean ARU score of 435, with 14.9% of participants achieving an ARU > 550, of which neither parameter reached statistical significance. There is the caveat that our participants were all healthy volunteers without any pre-existing comorbidity.
Currently, the decision whether to initiate LD ASA use for the primary prevention of CVD in middle-aged adults who have a 10% or greater 10-year CVD risk should be tailored to each individualized, as the net clinical benefit is marginal. The United States Preventive Services Task Force (USPSTF) recommends against the use of LD ASA for the primary prevention of CVD in older adults [40]. However, it is crucial to note that these overarching recommendations are derived from a completely different ethnic profile from that encountered in the Caribbean.
Important information including prospective data demonstrating that AR is detrimental, evidence that alternative antiplatelet therapies and strategies can achieve a clinical effect, and support for a reliable test that can assess AR status and predict outcomes is pivotal in attenuating CVD burden and MACE [41,42,43].
Study Limitations
Despite being powered for pharmacodynamic ARU values, this study was not designed for clinical outcomes and, thus, is limited with respect to external validity for the efficacy and safety of aspirin formulations in patients with CAD.
This study was of a prospective, open-label, single-arm crossover design. The study was not randomized or blinded, as there are currently no pharmaceutical division resources for interaction response technology, such as interaction web randomization services in this region. As a result, selection bias during enrolment and inaccurate estimates of the treatment effects of the two aspirin regimens can occur. Currently, there are also no contract research organizations (CROs) that operate within Trinidad and Tobago. Therefore, the study investigators decided to pursue an open-label, pragmatic study for transparency and supervised all other aspects, as there were no third-party entities to specifically coordinate randomization and/or blinding, as would be expected in large-scale trials. Conducting clinical trials, even small pilot studies, in the Caribbean is very difficult as there are limited resources with respect to grant financing, logistical planning, and experienced personnel who are qualified and trained in clinical trial management.
The study showed a predilection for Caribbean South Asian patients (68%), which is strikingly similar to other exploratory pilot studies performed by this group, suggestive of an inherent selection bias [15, 44,45,46].
Unfortunately, the prevalence of AR is contingent on the assay utilized, which has relatively poor inter-test reliability [32]. Comprehensive platelet function testing biochemical and pharmacokinetic data may prove to be more informative; however, due to several logistical issues, these are not currently available in Trinidad.
Conclusions
There were no statistically significant differences in aspirin resistance between Bayer® LD EC-ASA and Vazalore® LD PL-ASA. This dedicated pharmacodynamic study could be potentially informative for Caribbean patients on dual antiplatelet therapy (DAPT). Further prospective studies are required to confirm these results.
Data Availability
All available data can be obtained by contacting the corresponding author. All materials, data, code, and associated protocols will be made promptly available to the editor and readers upon request. If requested, there will not be any restrictions on the availability of materials.
References
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93–621.
ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–39.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–46.
Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, et al. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with adp receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation. 2015;132:174–81.
CURRENT-OASIS 7 Investigators, Mehta SR, Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.
Angiolillo DJ, Prats J, Deliargyris EN, Schneider DJ, Scheiman J, Kimmelstiel C, et al. Pharmacokinetic and pharmacodynamic profile of a novel phospholipid aspirin formulation. Clin Pharmacokinet. 2022;61:465–79.
Franchi F, Schneider DJ, Prats J, Fan W, Rollini F, Been L, et al. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study. J Thromb Thrombolysis. 2022;54:373–81.
[No title]. [cited 1 Apr 2024]. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/203697Orig1s009ltr.pdf.
Seecheran NA, Maharaj A, Boodhai B, Seecheran R, Seecheran V, Persad S, et al. Prevalence of clOpidogrel “resIstaNce” in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study. Open Heart. 2019;6: e000841.
Martinez-Amezcua P, Haque W, Khera R, Kanaya AM, Sattar N, Lam CSP, et al. The upcoming epidemic of heart failure in South Asia. Circ Heart Fail. 2020. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007218.
Jones D, Persad-Ramdeensingh S, Abrahim SC, Seecheran N, Haraksingh RR. Prevalence of CYP2C19*2 and CYP2C19*3 allelic variants and clopidogrel use in patients with cardiovascular disease in Trinidad & Tobago. Cardiol Ther. 2024;13:191–203.
ICH GCP Guidelines with Integrated Addendum E6(R2), Step 4, November 2016: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2): Current Step Version 4, Dated 9 November 2016. 2016.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.
Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 2008;123:267–73.
Seecheran NA, Sukha D, Grimaldos K, Grimaldos G, Richard S, Ishmael A, et al. Effect of cocoa (L.) on platelet function testing profiles in patients with coronary artery disease: ECLAIR pilot study. Open Heart. 2022. https://doi.org/10.1136/openhrt-2022-002066.
Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008. https://doi.org/10.1016/j.jacc.2007.11.080.
Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.
Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975;72:2994–8.
Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74:597–607.
Awtry EH, Loscalzo J. Aspirin. Circulation. 2000. https://doi.org/10.1161/01.CIR.101.10.1206.
Angiolillo DJ, Bhatt DL, Lanza F, Deliargyris EN, Prats J, Fan W, et al. Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. J Thromb Thrombolysis. 2020;49:337–43.
Lichtenberger LM. Development of the PC-NSAID technology: from contact angle to Vazalore®. Drug Discov Today. 2023;28: 103411.
Cryer B, Bhatt DL, Lanza FL, Dong J-F, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106:272–7.
Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med. 1995;1:154–8.
Angiolillo DJ, Bhatt DL, Lanza F, Cryer B, Dong J-F, Jeske W, et al. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019;48:554–62.
Schneider DJ, Taatjes-Sommer HS, Prats J, Deliargyris EN. Influence of lipid excipients on platelet function and the pharmacodynamic effects of aspirin. J Cardiovasc Pharmacol. 2021;78:297–301.
Khan H, Kanny O, Syed MH, Qadura M. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms231911317.
Schwartz KA. Aspirin resistance. Neurohospitalist. 2011. https://doi.org/10.1177/1941875210395776.
Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol. 2005. https://doi.org/10.1016/j.jacc.2004.08.070.
Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122–6.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002. https://doi.org/10.1161/01.CIR.0000013777.21160.07.
Tran HA, Anand SS, Hankey GJ, Eikelboom JW. Aspirin resistance. Thromb Res. 2007;120:337–46.
Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am J Med. 2007;120:1–4.
Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606–17.
Lee P-Y, Chen W-H, Ng W, Cheng X, Kwok JY-Y, Tse H-F, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118:723–727.
Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141:69–78.
Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv Hematol. 2009. https://doi.org/10.1155/2009/937352.
Xi C. Prevalence, profile, predictors, and natural history of aspirin resistance measured by the ultegra rapid platelet function assay-asa in patients with coronary artery disease. 2017.
Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol. 2003;92:1492–4.
US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327:1577–84.
Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation. 2006;113:2865–7.
Schrör K, Hohlfeld T, Weber A-A. Aspirin resistance—does it clinically matter? Clin Res Cardiol. 2006;95:505–10.
Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004;110:1706–8.
Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022. https://doi.org/10.1016/j.lana.2022.100252.
Seecheran N, Grimaldos K, Ali K, Grimaldos G, Richard S, Ishmael A, et al. The effect of dapagliflozin on platelet function testing profiles in diabetic patients: the EDGE pilot study. Cardiol Ther. 2021;10:561–8.
Seecheran N, Ramdeen A, Debideen N, Ali K, Grimaldos K, Grimaldos G, et al. The effect of empagliflozin on platelet function profiles in patients with stable coronary artery disease in Trinidad: the EFFECT pilot study. Cardiol Ther. 2021;10:189–99.
Acknowledgements
The investigators sincerely appreciate and remain grateful to the participants for their contribution to this clinical study.
Funding
No funding or sponsorship was received for the publication of this article. The Campus Research and Publication Fund Committee, at its meeting on June 23, 2023, received our grant application and agreed to approve (i) the grant for TT$46,350.00 from the Medical Sciences Fund for the four (4) VerifyNow ARU Kits for the project (CRP.3.JUN23.04—Aspirin Resistance in Trinidad: The ART Study).
Author information
Authors and Affiliations
Contributions
Naveen Seecheran and Penelope McCallum conceptualized and designed the study. Kathryn Grimaldos, Priya Ramcharan, Jessica Kawall, Arun Katwaroo, Valmiki Seecheran, Cathy-Lee Jagdeo, Salma Rafeeq, Rajeev Seecheran, Abel Leyva Quert, Nafeesah Ali, Lakshmipathi Peram, Shari Khan, Fareed Ali, Shastri Motilal, Neal Bhagwandass, Stanley Giddings, Anil Ramlackhansingh, Sherry Sandy conducted the study. Kathryn Grimaldos, Priya Ramcharan, Jessica Kawall, Arun Katwaroo, Valmiki Seecheran, Cathy-Lee Jagdeo, Salma Rafeeq, Rajeev Seecheran, Abel Leyva Quert, Nafeesah Ali, Lakshmipathi Peram, Shari Khan, Fareed Ali, Shastri Motilal, Neal Bhagwandass, Stanley Giddings, Anil Ramlackhansingh, Sherry Sandy reviewed the study. Naveen Seecheran and Penelope McCallum wrote the manuscript. Naveen Seecheran revised the manuscript. The guarantor, Naveen Seecheran, accepts full responsibility for the work and/or the conduct of the study, has access to the data, and controls the decision to publish.
Corresponding author
Ethics declarations
Conflict of Interest
Naveen Seecheran is an Editorial Board member of Cardiology and Therapy. Naveen Seecheran was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Penelope McCallum, Kathryn Grimaldos, Priya Ramcharan, Jessica Kawall, Arun Katwaroo, Valmiki Seecheran, Cathy-Lee Jagdeo, Salma Rafeeq, Rajeev Seecheran, Abel Leyva Quert, Nafeesah Ali, Lakshmipathi Peram, Shari Khan, Fareed Ali, Shastri Motilal, Neal Bhagwandass, Stanley Giddings, Anil Ramlackhansingh, Sherry Sandy have nothing to disclose with respect to personal, financial, commercial, or academic conflicts of interest.
Ethical Approval
The study complied accordingly with the Declaration of Helsinki, International Conference on Harmonization, Good Clinical Practice (ICH-GCP), and was authorized by the Campus Research Ethics Committee (CREC) of the University of the West Indies, St. Augustine (UWI STA), Trinidad (CEC1153/06/19). All participants provided written informed consent to participate in this clinical study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Seecheran, N., McCallum, P., Grimaldos, K. et al. Pharmacodynamic Comparison of Two Aspirin Formulations in the Caribbean: The ARC Study. Cardiol Ther 13, 593–602 (2024). https://doi.org/10.1007/s40119-024-00373-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40119-024-00373-6